Literature DB >> 24673542

Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients.

Hélène Monjanel1, Laure Deville, Caroline Ram-Wolff, Marie-Dominique Venon, Patricia Franchi, Claire Benet, Eric de Kerviler, Marion Malphettes, Catherine Thieblemont, Pauline Brice.   

Abstract

Entities:  

Keywords:  Hodgkin lymphoma; anaplastic large-cell lymphoma; brentuximab vedotin; monoclonal antibody; primary refractory

Mesh：

Substances：

Year:  2014        PMID： 24673542     DOI： 10.1111/bjh.12849

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  6 in total

1.  Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma.

Authors:  Anne-Sophie Michallet; Yann Guillermin; Benedicte Deau; Laure Lebras; Stephanie Harel; Sandy Amorin; Claire Reynes; Gilles Salles; Fabien Subtil; Pauline Brice
Journal:  Haematologica       Date:  2015-04-03       Impact factor: 9.941

2.  Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program.

Authors:  Aurore Perrot; Hélène Monjanel; Réda Bouabdallah; Philippe Quittet; Clémentine Sarkozy; Marc Bernard; Aspasia Stamatoullas; Cécile Borel; Krimo Bouabdallah; Emmanuelle Nicolas-Virelizier; Marion Fournier; Franck Morschhauser; Pauline Brice
Journal:  Haematologica       Date:  2016-01-14       Impact factor: 9.941

3.  Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia.

Authors:  Qing-Ming Yang; Jung Yong Hong; Young Hyeh Ko; Shek-Ying Lin; Wing-Yan Au; Moon Ki Choi; Silvia Park; Seok Jin Kim; Won Seog Kim
Journal:  Onco Targets Ther       Date:  2014-09-26       Impact factor: 4.147

4.  Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia.

Authors:  Zdeněk Král; Jozef Michalka; Heidi Móciková; Jana Marková; Alice Sýkorová; David Belada; Alexandra Jungová; Samuel Vokurka; Marie Lukášová; Vít Procházka; Juraj Ďuraš; Roman Hájek; Ladislav Dušek; Ľuboš Drgoňa; Miriam Ladická; Veronika Ballová; Andrej Vranovský
Journal:  J Cancer       Date:  2019-08-28       Impact factor: 4.207

Review 5.  Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy.

Authors:  Roser Velasco; Eva Domingo-Domenech; Anna Sureda
Journal:  Cancers (Basel)       Date:  2021-12-05       Impact factor: 6.639

Review 6.  Brentuximab vedotin: clinical updates and practical guidance.

Authors:  Jun Ho Yi; Seok Jin Kim; Won Seog Kim
Journal:  Blood Res       Date:  2017-12-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.